dotMD.com
Join Community
📖Formal Study Breakdown Talk in Gut, Labs & Supplements Space 711+ Logs • Free →🧮Lab Calculator ↓
Reading this clinical breakthrough? See how real patients are applying these numbers in real life. Compare real-world patient outcomes, lab numbers, and doctor visit tips—100% free with a private @handle and zero login wall.
Click to Ask a Question or Post Your Experience ▾
Post to Gut, Labs & Supplements Space (15 Seconds • No Account or Email Required)
Or read existing discussions in Gut, Labs & Supplements Space →
Back to Plain-English 8th-Grade Story
Google Scholar NIH PubMed #42716074
Official NIH NLM MEDLINE / PubMed Citation • PMID: 42716074

Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Lancet

Verbatim Formal Study Abstract

From Nov 17, 2020, to Sept 2, 2022, 1258 participants were enrolled and 948 were randomly assigned; 474 were randomly assigned to durvalumab and 474 to placebo.